Articles by tag: melanoma-treatment

iSCIB1+ DNA vaccine for melanoma: phase 3 approved by FDA

FDA approved phase 3 trials of iSCIB1+ DNA vaccine against melanoma. Survival increase of 24%. Find out when the drug will be available and who it will help.

Moderna vaccine shrank tumors in 83% of melanoma patients

mRNA drug mRNA-4359 with Keytruda showed 83% response and 17% complete remissions. Even PD-L1-negative tumors shrank. Learn how a ready-made vaccine teaches the immune system to attack cancer without personalization.